In its latest 13F filing, Commerzbank Aktiengesellschaft FI trimmed its stake in AbbVie by 30.5%, selling 39,586 shares and ending the quarter with 90,102 shares held. At the end of the period, the remaining position was valued at approximately 20.9 million dollars. This reduction contrasts with other institutional moves: Norges Bank initiated a multi-billion-dollar stake in Q2, Vanguard increased its holding by roughly 1.9%, and DZ BANK more than doubled its shares, highlighting divergent sentiment among large investors.

During the third quarter, AbbVie reported earnings per share of 1.86, beating consensus by nine cents, while revenue reached 15.78 billion, up 9.1% year-over-year and surpassing analyst estimates by 200 million. The company’s net margin held at around 4%, and return on equity exceeded 3,200%, driven in part by continued strength in its immunology franchise. Management reaffirmed Fourth-quarter EPS guidance in a range that implies mid-single-digit growth, and full-year consensus forecasts now project annual EPS north of 12.3, reflecting durable cash flows from core therapies.

AbbVie declared a quarterly dividend of 1.73 per share, marking a 5.5% raise from the prior distribution and translating to an annualized payout of 6.92, or a yield in the low single digits. The record date is January 16, with payment on February 17. Despite a payout ratio that exceeds five times trailing earnings, the board emphasized the company’s commitment to returning excess capital and maintaining its status among the highest-yielding large-cap healthcare names.

Among 23 research reports surveyed, two firms assign a Strong Buy rating to AbbVie, thirteen rate it Buy, and eight recommend Hold, resulting in a consensus view of Moderate Buy. Price targets range narrowly around the mid-to-upper 240s, reflecting both optimism about pipeline contributions—particularly in oncology and neuroscience—and caution around patent cliffs in key immunology products.